coteau ARQ.

OBX

Obsidian Therapeutics, Inc.
$13.98
+$0.04 (0.29%) Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-34%-1%+33%+66%+100%Jul 27Oct 23Sep 952w low $11.52
OBXSPY
Wall St. Highest PT $43.00 (+207.6%) Wall St. Avg PT $39.00 (+179.0%)
$12$23$35$46$58POC $18Hi $43Avg $39
Underwater Drawdown %Max DD -66.4%Current -60.1%
0.0%-66.4%
Relative Strength vs SPY-23.2% vs SPYUnderperforming
+110%0%-110%
1W
+$2.21 (18.78%)
1M
−$1.28 (8.39%)
3M
–
6M
–
YTD
–
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Analyst price targets
Current price$13.98
Average target$39.00
+$25.02 (+179.0%) upsideaverage target vs current price
CurrentAverageMedian
Low$32.00
Median$39.00
High$43.00
12-month Wall Street target range
Recent analyst rating changes · 4
Initiated
2026-09-22 · Leerink Partners started covering OBX at Outperform
Initiated
2026-09-09 · William Blair started covering OBX at Outperform
Initiated
2026-08-18 · LifeSci Capital started covering OBX at Outperform
Initiated
2026-08-05 · Piper Sandler started covering OBX at Overweight
All analyst rating changes ›

Third-party ratings, not Coteau's views.

Key stats & company

Market value$863.6M
P/E (next 12 months, estimated)-6.6
52-week range$11.52 – $49.97
Dividend yieldNo dividend
Average analyst price target$39.00 (+179%)

What they do

Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluated in clinical trials for advanced solid tumors, advanced melanoma, and relapsed refractory non-small cell lung cancer.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for OBX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 Coteau Physical AI Grid & Power
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

Earnings & events

OBX earningsNo upcoming date on file
Last 4 quarters · EPS vs estimate
Aug 28, 2026-$1.19est -$1.63+27.2%Above estimates
Nov 14, 2023-$94.03est -$113.18+16.9%Above estimates
Aug 14, 2023-$136.77est -$107.80−26.9%Below estimates
May 11, 2023-$142.47est -$122.45−16.4%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-24 02:38:55 ET
22-0522-0822-1123-0323-0523-0823-1126-08-170.960.00
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-03-31$0–
2025-03-31$0–

News & catalysts

More news
KBRA Assigns Preliminary Ratings to OBX 2026-NQM16 Trust
Business Wire · Oct 15
KBRA Assigns Preliminary Ratings to OBX 2026-J3 Trust
Business Wire · Oct 13
Obsidian Therapeutics to Present Updated Amsoki-cel (OBX-115) Phase 1/2 Data in Advanced Melanoma at SITC 2026 Annual Meeting
Business Wire · Oct 02
KBRA Assigns Preliminary Ratings to OBX 2026-NQM15 Trust
Business Wire · Sep 28
KBRA Assigns Preliminary Ratings to OBX 2026-INV6 Trust
Business Wire · Sep 24
Rating changes
Initiated
2026-09-22 · Leerink Partners started covering OBX at Outperform
Initiated
2026-09-09 · William Blair started covering OBX at Outperform
Initiated
2026-08-18 · LifeSci Capital started covering OBX at Outperform
Initiated
2026-08-05 · Piper Sandler started covering OBX at Overweight

Third-party analyst actions, not Coteau's views. All rating changes

Stats refreshed 2026-10-24 02:38:55 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, Coteau model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026